Publications by authors named "Rodrigo Santamaria Vicente"
Article Synopsis
- Luminal A breast cancer has a good outlook, but around 10% of patients may have tumors come back after 10 years, especially within the first 5 years after diagnosis.
- A study was done to see how a specific protein called NCAPH affects the growth of luminal A breast cancer, looking for gene patterns that could indicate a higher risk of bad outcomes.
- The findings showed that high levels of NCAPH are linked to more aggressive tumors and poorer responses to chemotherapy, leading to a new gene score (GSLA10) that can help predict which patients might have worse outcomes.
Despite their generally favorable prognosis, luminal A tumors paradoxically pose the highest ten-year recurrence risk among breast cancers. From those that relapse, a quarter of them do it within five years after diagnosis. Identifying such patients is crucial, as long-term relapsers could benefit from extended hormone therapy, whereas early relapsers may require aggressive treatment.
View Article and Find Full Text PDF